Romark is among the many companies working to respond to the novel coronavirus global health emergency. Romark has on-going clinical studies of its investigational new drug candidate NT-300 (nitazoxanide extended-release) for both the prevention and treatment of COVID-19 and other viral respiratory illnesses. See below for more information.
Romark completed its clinical trial of NT-300 (nitazoxanide extended-release) in the treatment of mild or moderate COVID-19.
Information about the trial is available at the following link:
Romark also has on-going Phase 3 clinical trials of NT-300 (nitazoxanide extended-release tablets) for the prevention of COVID-19 and the treatment of viral respiratory illnesses caused by rhinoviruses and other enteroviruses.
Information about the trials is available at the following links:
1) Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long Term Care Facilities
2) Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection
3) Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection